FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 1 of 4 ATTY, DOCKET NO. PAT033277-US-PCT

APPLICATION NO. 10/564337

APPLICANT Sedelmeier, Gottfried FILING DATE July 15, 2004

Group 1626

			U.S. PA	TENT DOCUMENTS		***************************************		***************************************
EXAMINER INITIAL	·····	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILI	NG DATE
	AA							
	AB							
	AC.							
	AD							
	AE							
7	AF							***************************************
	AG							•••••
	АН							***************************************
	ΑI							
	AJ							
	AK				***			
	AL							******
			FOREIGN	PATENT DOCUMENTS	····•			
		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
	AM							
								·
	AN							
	AN AO							
								·}
	AO							
	AO AP	OTHER DOC	JMENTS (inc	luding Author, Title, Date, Perti	nent pages, E	tc.)		
/SY/	AO AP	Pfizer Corp., AU 8656-	100-A: New b	luding Author, Title, Date, Perti enzothiazine-dioxide cpd. E biratory distress syndrome,	lipoxyaeno	se inhibitors	Useful	in
/SY/	AO AP AQ	Pfizer Corp., AU 8656- treating allergic asthma (2004)	100-A: New b a and adult rep	enzothiazine-dioxide cpd. §	lipoxygeno etc.; Derwe	se inhibitors int Publication	useful	in
	AO AP AQ AR	Pfizer Corp., AU 8656- treating allergic asthma (2004) Ciba Geigy, AG; SU-49 DEMKO, Z. et al; "Sim	100-A: New b a and adult rep 97-775: Tetraz ple preparation	enzothiazine-dioxide cpd. { biratory distress syndrome,	ilpoxygeno etc.; Derwe , Derwent F	use inhibitors ant Publication Aublications, L triles in wate	useful ns, Ltd.	in

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.